Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Office 1R203, Miami, FL, 33176, USA.
Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Sci Rep. 2022 Mar 16;12(1):4567. doi: 10.1038/s41598-022-08507-3.
The unique acute effects of the large fractional doses that characterize stereotactic radiosurgery (SRS) or radiotherapy (SRT), specifically in terms of antitumor immune cellular processes, vascular damage, tumor necrosis, and apoptosis on brain metastasis have yet to be empirically demonstrated. The objective of this study is to provide the first in-human evaluation of the acute biological effects of SRS/SRT in resected brain metastasis. Tumor samples from patients who underwent dose-escalated preoperative SRT followed by resection with available non-irradiated primary tumor tissues were retrieved from our institutional biorepository. All primary tumors and irradiated metastases were evaluated for the following parameters: tumor necrosis, T-cells, natural killer cells, vessel density, vascular endothelial growth factor, and apoptotic factors. Twenty-two patients with irradiated and resected brain metastases and paired non-irradiated primary tumor samples met inclusion criteria. Patients underwent a median preoperative SRT dose of 18 Gy (Range: 15-20 Gy) in 1 fraction, with 3 patients receiving 27-30 Gy in 3-5 fractions, followed by resection within median interval of 67.8 h (R: 18.25-160.61 h). The rate of necrosis was significantly higher in irradiated brain metastases than non-irradiated primary tumors (p < 0.001). Decreases in all immunomodulatory cell populations were found in irradiated metastases compared to primary tumors: CD3 + (p = 0.003), CD4 + (p = 0.01), and CD8 + (p = 0.01). Pre-operative SRT is associated with acute effects such as increased tumor necrosis and differences in expression of immunomodulatory factors, an effect that does not appear to be time dependent, within the limited intervals explored within the context of this analysis.
立体定向放射外科(SRS)或放射治疗(SRT)所特有的大分数剂量的独特急性效应,特别是在抗肿瘤免疫细胞过程、血管损伤、肿瘤坏死和细胞凋亡方面,对脑转移瘤尚未得到经验性证实。本研究的目的是首次在人类中评估 SRS/SRT 对切除的脑转移瘤的急性生物学效应。从我们的机构生物库中检索了接受递增剂量术前 SRT 治疗后行切除术且有可利用的未照射原发肿瘤组织的患者的肿瘤样本。所有原发性肿瘤和照射转移瘤均评估了以下参数:肿瘤坏死、T 细胞、自然杀伤细胞、血管密度、血管内皮生长因子和凋亡因子。22 例接受照射和切除脑转移瘤及配对未照射原发肿瘤样本的患者符合纳入标准。患者接受中位数为 18 Gy(范围:15-20 Gy)的单次术前 SRT 剂量(中位数:18 Gy;范围:15-20 Gy),3 例患者接受 27-30 Gy 的 3-5 次分割,然后在中位数间隔 67.8 h(范围:18.25-160.61 h)内行切除术。照射的脑转移瘤中的坏死率明显高于未照射的原发肿瘤(p<0.001)。与原发肿瘤相比,照射转移瘤中的所有免疫调节细胞群均减少:CD3+(p=0.003)、CD4+(p=0.01)和 CD8+(p=0.01)。术前 SRT 与急性效应相关,如肿瘤坏死增加和免疫调节因子表达的差异,在本分析中所探讨的有限时间间隔内,这种效应似乎与时间无关。